Uni-Bio Science Group Limited provided unaudited consolidated earnings guidance for the year ended 31 December 2023. For the year, the company expects to record a profit attributable to the owners of the parent of not less than HKD 60 million (2022: profit of HKD 38.51 million) for the Year. Based on the information available to the Board, the Board considers such expected increase was mainly attributable to an increase in sales revenue of not less than about 10% over that in 2022.

The sales revenue in the same period of 2022 was HKD 440 million,and the increase in revenue was mainly due to the Company's continuous expansion of hospital coverage and applicable patient population through academic promotion, which was fully recognised by the market and patients; the Group continued to optimize and control production costs, continuously deepen cooperation with raw material suppliers, and reduce the procurement cost of the Active Pharmaceutical Ingredient; and the Group achieved CMO revenue of more than HKD 9 million, representing an increase of not less than about 200% over corresponding period of 2022, or an increase of more than HKD 6 million.